Literature DB >> 29116478

Cyclodextrin polymers as nanocarriers for sorafenib.

Valentina Giglio1, Maurizio Viale2, Vittorio Bertone3, Irena Maric2, Rita Vaccarone3, Graziella Vecchio4.   

Abstract

Polymeric nanoparticles based on cyclodextrins are currently undergoing clinical trials as new promising nanotherapeutics. In light of this interest, we investigated cyclodextrin cross-linked polymers with different lengths as carriers for the poorly water-soluble drug sorafenib. Both polymers significantly enhanced sorafenib solubility, with shorter polymers showing the most effective solubilizing effect. Inclusion complexes between sorafenib and the investigated polymers exhibited an antiproliferative effect in tumor cells similar to that of free sorafenib. Polymer/Sorafenib complexes also showed lower in vivo tissue toxicity than with free sorafenib in all organs. Our results suggest that the inclusion of sorafenib in polymers represents a successful strategy for a new formulation of this drug.

Entities:  

Keywords:  Anticancer drug; Drug carriers; Nanoparticles; Solubility; Toxicity

Mesh：

Substances：

Year:  2017        PMID： 29116478     DOI： 10.1007/s10637-017-0538-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  41 in total

1.  Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery.

Authors:  Resmi Anand; Milo Malanga; Ilse Manet; Francesco Manoli; Kata Tuza; Ahmet Aykaç; C Ladavière; Eva Fenyvesi; Antonio Vargas-Berenguel; Ruxandra Gref; Sandra Monti
Journal:  Photochem Photobiol Sci       Date:  2013-10       Impact factor: 3.982

Review 2.  Recent advances in cyclodextrin delivery techniques.

Authors:  Hidetoshi Arima; Yuya Hayashi; Taishi Higashi; Keiichi Motoyama
Journal:  Expert Opin Drug Deliv       Date:  2015-06-22       Impact factor: 6.648

Review 3.  Cyclodextrin nanosystems in oral drug delivery: A mini review.

Authors:  Oluwatomide Adeoye; Helena Cabral-Marques
Journal:  Int J Pharm       Date:  2017-04-26       Impact factor: 5.875

4.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

Review 5.  Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications.

Authors:  Frank van de Manakker; Tina Vermonden; Cornelus F van Nostrum; Wim E Hennink
Journal:  Biomacromolecules       Date:  2009-12-14       Impact factor: 6.988

6.  Dextran-based cyclodextrin polymers: their solubilizing effect and self-association.

Authors:  Zoltán Fülöp; Thorbjørn T Nielsen; Kim L Larsen; Thorsteinn Loftsson
Journal:  Carbohydr Polym       Date:  2013-05-27       Impact factor: 9.381

Review 7.  Toxicity of sorafenib: clinical and molecular aspects.

Authors:  Benoit Blanchet; Bertrand Billemont; Stéphane Barete; Hélène Garrigue; Laure Cabanes; Romain Coriat; Camille Francès; Bertrand Knebelmann; François Goldwasser
Journal:  Expert Opin Drug Saf       Date:  2010-03       Impact factor: 4.250

8.  CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.

Authors:  Andrew J Clark; Devin T Wiley; Jonathan E Zuckerman; Paul Webster; Joseph Chao; James Lin; Yun Yen; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-21       Impact factor: 11.205

Review 9.  Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.

Authors:  Olivier Huillard; Emilie Boissier; Benoit Blanchet; Audrey Thomas-Schoemann; Anatole Cessot; Pascaline Boudou-Rouquette; Jean-Philippe Durand; Romain Coriat; Julie Giroux; Jerome Alexandre; Michel Vidal; Francois Goldwasser
Journal:  Expert Opin Drug Saf       Date:  2014-04-03       Impact factor: 4.250

10.  Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.

Authors:  Jeremy D Heidel; Thomas Schluep
Journal:  J Drug Deliv       Date:  2012-02-02
View more
  11 in total

1.  Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy.

Authors:  Maurizio Viale; Rita Tosto; Valentina Giglio; Giuseppe Pappalardo; Valentina Oliveri; Irena Maric; Maria Addolorata Mariggiò; Graziella Vecchio
Journal:  Invest New Drugs       Date:  2018-12-17       Impact factor: 3.850

2.  Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity.

Authors:  Maurizio Viale; Graziella Vecchio; Massimiliano Monticone; Vittorio Bertone; Valentina Giglio; Irena Maric; Michele Cilli; Vittorio Bocchini; Aldo Profumo; Mirco Ponzoni; Laura Emionite; Mattia Rocco
Journal:  Pharm Res       Date:  2019-06-03       Impact factor: 4.200

3.  Understanding Surface Interaction and Inclusion Complexes between Piroxicam and Native or Crosslinked β-Cyclodextrins: The Role of Drug Concentration.

Authors:  Giuseppina Raffaini; Fabio Ganazzoli
Journal:  Molecules       Date:  2020-06-19       Impact factor: 4.411

4.  A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells.

Authors:  Yanli Wang; Zigui Tang
Journal:  Onco Targets Ther       Date:  2018-11-29       Impact factor: 4.147

5.  The Biological Fate of Pharmaceutical Excipient β-Cyclodextrin: Pharmacokinetics, Tissue Distribution, Excretion, and Metabolism of β-Cyclodextrin in Rats.

Authors:  Kunqian Mu; Kaiwen Jiang; Yue Wang; Zihan Zhao; Song Cang; Kaishun Bi; Qing Li; Ran Liu
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

6.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29

7.  Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.

Authors:  Zhuo-Yue Li; Yi-Fan Yin; Yang Guo; Hui Li; Mei-Qi Xu; Man Liu; Jing-Ru Wang; Zhen-Han Feng; Xiao-Chuan Duan; Shuang Zhang; Shuai-Qiang Zhang; Guang-Xue Wang; Ai Liao; Shu-Min Wang; Xuan Zhang
Journal:  Int J Nanomedicine       Date:  2020-03-16

8.  Exploring Charged Polymeric Cyclodextrins for Biomedical Applications.

Authors:  Noemi Bognanni; Francesco Bellia; Maurizio Viale; Nadia Bertola; Graziella Vecchio
Journal:  Molecules       Date:  2021-03-19       Impact factor: 4.411

9.  Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer.

Authors:  Jun Wang; Fengmei Lv; Tao Sun; Shoujin Zhao; Haini Chen; Yu Liu; Zhepeng Liu
Journal:  Nanomaterials (Basel)       Date:  2021-12-01       Impact factor: 5.076

Review 10.  Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.

Authors:  Daniel Andrés Real; Karen Bolaños; Josefina Priotti; Nicolás Yutronic; Marcelo J Kogan; Rodrigo Sierpe; Orlando Donoso-González
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.